Zomedica closes acquisition of Revo Squared for $6M cash plus warrants, earn-outs up to $4M

Zomedica Corp.

Completed acquisition of Revo Squared on July 1, 2022 for $6M base cash, subject to working capital adjustments.
Issued 10-year warrant to Revo Squared for 10M common shares at $0.2201 per share.
Earn-out payments up to $4M: $2M each when Revo net sales exceed $5M and $10M in any calendar year through 2027.
Revo's MicroView digital cytology platform automates slide preparation; manufacturing moving to Roswell, GA facility.
Company expects to launch MicroView to veterinary market in 2023.

item 2.01 item 3.02 item 1.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.